awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q53786874-15E3C7EA-4F9D-419A-A8B6-CDE576054303
Q53786874-15E3C7EA-4F9D-419A-A8B6-CDE576054303
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53786874-15E3C7EA-4F9D-419A-A8B6-CDE576054303
Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.
P2860
Q53786874-15E3C7EA-4F9D-419A-A8B6-CDE576054303
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53786874-15E3C7EA-4F9D-419A-A8B6-CDE576054303
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ecdb0433a18e89e9d2969dae90443410f832abbd
P2860
The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2